Holen Sie sich die Stockscreener-App
2.83
1.43%
0.04
Handel nachbörslich:
2.93
0.10
+3.53%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CTXR?
Forum
Prognose
Aktiensplit
Citius Pharmaceuticals Inc Aktie (CTXR) Neueste Nachrichten
Amendment: SEC Form 10-K/A filed by Citius Pharmaceuticals Inc. - Quantisnow
Short Interest in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Expands By 13.6% - Defense World
Citius Pharmaceuticals (STU:47N0) Earnings Yield (Joel Gree - GuruFocus.com
Citius Pharmaceuticals Completes Registered Direct Offering, Raises $2.7 MillionOn January 7, 2025, Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) announced the closure of a securities purchase agreement with certain institutional investors for a regist - Defense World
Citius Pharmaceuticals’ (CTXR) Buy Rating Reiterated at D. Boral Capital - Defense World
Citius Pharma secures $3 million in direct offering By Investing.com - Investing.com Nigeria
Citius Pharmaceuticals (NASDAQ: CTXR) Announces Progress in LYMPHIR Commercial Launch Preparation - Defense World
Why Citius Pharmaceuticals (CTXR) Stock Is Down 15% - Benzinga
Citius Pharma secures $3 million in direct offering - Investing.com
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules - PR Newswire
Citius Pharmaceuticals Secures $3M Through Strategic Share Offering with 5-Year Warrants - StockTitan
Citius Pharma gears up for LYMPHIR immunotherapy launch By Investing.com - Investing.com Australia
Citius Pharma gears up for LYMPHIR immunotherapy launch - Investing.com
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025 - PR Newswire
Citius Oncology to explore strategic alternatives - Yahoo Finance
Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives - The Malaysian Reserve
Citius Oncology Explores Strategic Options with Jefferies Following LYMPHIR FDA Approval - StockTitan
Citius Pharma Reports 2024 Financial Results and Business Update - MSN
Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital - Yahoo Finance
Citius Pharmaceuticals (NASDAQ:CTXR) Upgraded to “Buy” at D. Boral Capital - Defense World
D. Boral Capital Upgrades Citius Pharmaceuticals (CTXR) - MSN
This American Airlines Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday - Benzinga
American Air upgraded, Nordstrom downgraded: Wall Street's top analyst calls - Yahoo Finance
Citius Pharmaceuticals upgraded by D. Boral Capital with a new price target - Quantisnow
CCSC Technology International, CEL-SCI And 3 Stocks To Watch Heading Into Monday - Benzinga
Citius Pharmaceuticals (NASDAQ: CTXR) Reports Fiscal Full Year 2024 Financial Results and Provides Business Update - Defense World
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update - The Malaysian Reserve
Citius Oncology, Inc. Reports Earnings Results for the Full Year Ended September 30, 2024 - Marketscreener.com
Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Re - GuruFocus.com
Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update - The Malaysian Reserve
Citius Pharmaceuticals Inc. (CTXR) reports earnings - Quartz
Citius Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended September 30, 2024 - Marketscreener.com
Market Sentiment Around Loss-Making Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) - Yahoo Finance
Citius Pharmaceuticals Regains Compliance with Nasdaq Listing Rule 5550(a)(2) - Defense World
Citius Pharmaceuticals (NASDAQ:CTXR) Stock Price Down 5.1% – Here’s What Happened - Defense World
Citius Pharmaceuticals stock hits 52-week low at $2.52 By Investing.com - Investing.com Canada
Citius Pharmaceuticals stock hits 52-week low at $2.52 - Investing.com
Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering - The Eastern Progress Online
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology - The Eastern Progress Online
Analysts Hunt for Undervalued Biotech Stocks - Marketscreener.com
Citius Pharmaceuticals (FRA:47N0) Enterprise Value : €9.75 Mil (As of Nov. 28, 2024) - GuruFocus.com
Citius Pharmaceuticals (FRA:47N0) Earnings Yield (Joel Gree - GuruFocus.com
Citius Pharmaceuticals (FRA:47N0) 3-Year EPS without NRI Gr - GuruFocus.com
Citius Pharmaceuticals (FRA:47N0) Cyclically Adjusted Reven - GuruFocus.com
Citius Pharmaceuticals (FRA:47N0) Total Inventories : €0.00 Mil (As of Jun. 2024) - GuruFocus.com
Hemorrhoids Market Expected to Experience Major Growth by 2032, - openPR
Citius Pharmaceuticals, Inc. Announces FDA Acceptance of the BLA Resubmission of LYMPHIR (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma - Marketscreener.com
Citius Pharmaceuticals Appoints John Laffey to the ARDS Scientific Advisory Board - Marketscreener.com
Citius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma - Marketscreener.com
Citius Pharmaceuticals, Inc. Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids - Marketscreener.com
Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution - Marketscreener.com
Citius Pharmaceuticals, Inc. Appoints Jaime Bartushak as the Chief Financial Officer and Principal Financial Officer - Marketscreener.com
5.49%
0.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):